Global Pruritus Therapeutic Market 2017-2021
出 版 商：Technavio
出版日期：2017/08/02
頁 數：81頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 5,000 (Global-User License)
About Global Pruritus Therapeutic
Pruritus is defined as the unpleasant skin sensation that frequently provokes scratching. Various systemic diseases are the major cause of pruritus. The intensity of sensation ranges from mild to severe. Various diseases cause changes/imbalance of biochemical factors, which trigger skin sensation and lead to pruritus. The market is segmented based on these disease conditions, which are responsible for pruritus.
Technavio’s analysts forecast the global pruritus therapeutic market to grow at a CAGR of 4.95% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global pruritus therapeutic market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Pruritus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Allergan
‧ GlaxoSmithKline
‧ Pfizer
‧ Sanofi
Other prominent vendors
‧ Abbott
‧ Ajanta Pharma
‧ Almirall
‧ Astellas Pharma
‧ Bristol-Myers Squibb
‧ CARA Therapeutic
‧ Cipla
‧ Eisai
‧ Eli Lilly
‧ Galderma
‧ Glenmark
‧ Heron Therapeutic
‧ IPCA
‧ Lupin
‧ Merck
‧ Novartis
‧ Sun Pharma
‧ Takeda Pharmaceutical
Market driver
‧ Drug-induced pruritus
‧ For a full, detailed list, view our report
Market challenge
‧ Poor patient adherence due to inadequate information on drug usage
‧ For a full, detailed list, view our report
Market trend
‧ Incorporation of novel technology for product development
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Pruritus is defined as the unpleasant skin sensation that frequently provokes scratching. Various systemic diseases are the major cause of pruritus. The intensity of sensation ranges from mild to severe. Various diseases cause changes/imbalance of biochemical factors, which trigger skin sensation and lead to pruritus. The market is segmented based on these disease conditions, which are responsible for pruritus.
Technavio’s analysts forecast the global pruritus therapeutic market to grow at a CAGR of 4.95% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global pruritus therapeutic market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA
Technavio's report, Global Pruritus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
‧ Allergan
‧ GlaxoSmithKline
‧ Pfizer
‧ Sanofi
Other prominent vendors
‧ Abbott
‧ Ajanta Pharma
‧ Almirall
‧ Astellas Pharma
‧ Bristol-Myers Squibb
‧ CARA Therapeutic
‧ Cipla
‧ Eisai
‧ Eli Lilly
‧ Galderma
‧ Glenmark
‧ Heron Therapeutic
‧ IPCA
‧ Lupin
‧ Merck
‧ Novartis
‧ Sun Pharma
‧ Takeda Pharmaceutical
Market driver
‧ Drug-induced pruritus
‧ For a full, detailed list, view our report
Market challenge
‧ Poor patient adherence due to inadequate information on drug usage
‧ For a full, detailed list, view our report
Market trend
‧ Incorporation of novel technology for product development
‧ For a full, detailed list, view our report
Key questions answered in this report
‧ What will the market size be in 2021 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market overview
‧ Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by disease type
‧ Renal pruritus
‧ Cholestatic pruritus
‧ Hematologic pruritus
‧ Endocrine pruritus
‧ Oncological pruritus
PART 08: Market segmentation by route of administration (ROA)
PART 09: Geographical segmentation
‧ Pruritus therapeutic market in Americas
‧ Pruritus therapeutic market in EMEA
‧ Pruritus therapeutic market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 12: Market trends
‧ Identification of new T-cell subsets (Th17 and Th22)
‧ Incorporation of novel technology for product development
‧ Inorganic growth strategies
PART 13: Vendor landscape
‧ Competitive scenario
PART 14: Key vendor analysis
‧ Allergan
‧ GlaxoSmithKline
‧ Pfizer
‧ Sanofi
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits?
Exhibit 01: Types of pruritus based on causative disease
Exhibit 02: Chemical substances that trigger pruritus
Exhibit 03: Major diseases that cause pruritus
Exhibit 04: Major drug classes that induce pruritus
Exhibit 05: Global pruritus therapeutic market drivers
Exhibit 06: Global pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis in global pruritus therapeutic market
Exhibit 08: Five forces analysis
Exhibit 09: Pipeline molecules based on vendors
Exhibit 10: Key clinical trials
Exhibit 11: Segmentation of global pruritus therapeutic market by disease type 2016
Exhibit 12: Segmentation of global pruritus therapeutic market share by disease type 2016
Exhibit 13: Global renal pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 14: Global cholestatic pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 15: Global hematologic pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 16: Global endocrine pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 17: Global oncological pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 18: Various ROAs applied for pruritic drugs 2016
Exhibit 19: Segmentation of global pruritus therapeutic market by geography 2016 and 2021
Exhibit 20: Global pruritus therapeutic market revenue by geography 2016-2021 ($ millions)
Exhibit 21: Market scenario in Americas
Exhibit 22: Pruritus therapeutic market in Americas 2016-2021 ($ millions)
Exhibit 23: Market scenario in EMEA
Exhibit 24: Pruritus therapeutic market in EMEA 2016-2021 ($ millions)
Exhibit 25: Market scenario in APAC
Exhibit 26: Pruritus therapeutic market in APAC 2016-2021 ($ millions)
Exhibit 27: Prevalence of pruritus in various disease conditions
Exhibit 28: Various drugs responsible for inducing pruritus
Exhibit 29: Phase III drugs for management of pruritus
Exhibit 30: Global sales of Allegra 2008 and 2016 ($ millions)
Exhibit 31: Role of newer T-cell subsets in dermatological diseases
Exhibit 32: Inorganic growth strategies
Exhibit 33: Competitive structure analysis of global pruritus therapeutic market 2016
Exhibit 34: Market penetration of various global pruritus therapeutic manufacturers 2016
Exhibit 35: Strategic success factors of companies in global pruritus therapeutic market
Exhibit 36: Allergan: Key highlights
Exhibit 37: Allergan: Strength assessment
Exhibit 38: Allergan: Strategy assessment
Exhibit 39: Allergan: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Pfizer: Key highlights
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Sanofi: Key highlights
Exhibit 49: Sanofi: Strength assessment
Exhibit 50: Sanofi: strategy assessment
Exhibit 51: Sanofi: opportunity assessment
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market overview
‧ Five forces analysis
PART 06: Pipeline landscape
PART 07: Market segmentation by disease type
‧ Renal pruritus
‧ Cholestatic pruritus
‧ Hematologic pruritus
‧ Endocrine pruritus
‧ Oncological pruritus
PART 08: Market segmentation by route of administration (ROA)
PART 09: Geographical segmentation
‧ Pruritus therapeutic market in Americas
‧ Pruritus therapeutic market in EMEA
‧ Pruritus therapeutic market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
‧ Market drivers
‧ Market challenges
PART 12: Market trends
‧ Identification of new T-cell subsets (Th17 and Th22)
‧ Incorporation of novel technology for product development
‧ Inorganic growth strategies
PART 13: Vendor landscape
‧ Competitive scenario
PART 14: Key vendor analysis
‧ Allergan
‧ GlaxoSmithKline
‧ Pfizer
‧ Sanofi
‧ Other prominent vendors
PART 15: Appendix
‧ List of abbreviations
List of Exhibits?
Exhibit 01: Types of pruritus based on causative disease
Exhibit 02: Chemical substances that trigger pruritus
Exhibit 03: Major diseases that cause pruritus
Exhibit 04: Major drug classes that induce pruritus
Exhibit 05: Global pruritus therapeutic market drivers
Exhibit 06: Global pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis in global pruritus therapeutic market
Exhibit 08: Five forces analysis
Exhibit 09: Pipeline molecules based on vendors
Exhibit 10: Key clinical trials
Exhibit 11: Segmentation of global pruritus therapeutic market by disease type 2016
Exhibit 12: Segmentation of global pruritus therapeutic market share by disease type 2016
Exhibit 13: Global renal pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 14: Global cholestatic pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 15: Global hematologic pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 16: Global endocrine pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 17: Global oncological pruritus therapeutic market 2016-2021 ($ millions)
Exhibit 18: Various ROAs applied for pruritic drugs 2016
Exhibit 19: Segmentation of global pruritus therapeutic market by geography 2016 and 2021
Exhibit 20: Global pruritus therapeutic market revenue by geography 2016-2021 ($ millions)
Exhibit 21: Market scenario in Americas
Exhibit 22: Pruritus therapeutic market in Americas 2016-2021 ($ millions)
Exhibit 23: Market scenario in EMEA
Exhibit 24: Pruritus therapeutic market in EMEA 2016-2021 ($ millions)
Exhibit 25: Market scenario in APAC
Exhibit 26: Pruritus therapeutic market in APAC 2016-2021 ($ millions)
Exhibit 27: Prevalence of pruritus in various disease conditions
Exhibit 28: Various drugs responsible for inducing pruritus
Exhibit 29: Phase III drugs for management of pruritus
Exhibit 30: Global sales of Allegra 2008 and 2016 ($ millions)
Exhibit 31: Role of newer T-cell subsets in dermatological diseases
Exhibit 32: Inorganic growth strategies
Exhibit 33: Competitive structure analysis of global pruritus therapeutic market 2016
Exhibit 34: Market penetration of various global pruritus therapeutic manufacturers 2016
Exhibit 35: Strategic success factors of companies in global pruritus therapeutic market
Exhibit 36: Allergan: Key highlights
Exhibit 37: Allergan: Strength assessment
Exhibit 38: Allergan: Strategy assessment
Exhibit 39: Allergan: Opportunity assessment
Exhibit 40: GlaxoSmithKline: Key highlights
Exhibit 41: GlaxoSmithKline: Strength assessment
Exhibit 42: GlaxoSmithKline: Strategy assessment
Exhibit 43: GlaxoSmithKline: Opportunity assessment
Exhibit 44: Pfizer: Key highlights
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Sanofi: Key highlights
Exhibit 49: Sanofi: Strength assessment
Exhibit 50: Sanofi: strategy assessment
Exhibit 51: Sanofi: opportunity assessment
